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ABSTRACT
Introduction: Novartis recently launched Novartis
Access, an initiative to provide a basket of reduced
price medicines for non-communicable diseases
(NCDs) to be sold through the public and private non-
profit sectors in programme countries. This study will
evaluate the impact of Novartis Access on the
availability and price of NCD medicines at health
facilities and households in Kenya, the first country to
receive the programme.
Methods and analysis: This study will be a cluster-
randomised controlled trial. 8 counties in Kenya will be
randomly assigned to the intervention or control group
using a covariate constrained randomisation method to
maximise balance on demographic and health
characteristics. In intervention counties, public and
private non-profit health facilities will be able to order
Novartis Access NCD medicines from the Mission for
Essential Drugs and Supplies (MEDS). Data will be
collected from a random sample of 384 health facilities
and 800 households at baseline, midline after 1-year of
intervention, and end-line after 2 years. Quarterly
surveillance data will also be collected from health
facilities and a subsample of households through
phone-based interviews. Households will be eligible if
at least one resident has been previously diagnosed
and prescribed a medicine for an NCD addressed by
Novartis Access, including hypertension and diabetes.
The primary outcomes will be availability and price of
NCD medicines at health facilities, and availability,
price, and expenditures on NCD medicines at
households. Impacts will be estimated using intention-
to-treat analysis.
Ethics and dissemination: This protocol was
approved by the Institutional Review Boards at
Strathmore University and at Boston University.
Informed consent will be obtained from all participants
at the start of the trial. The findings of the trial will be
disseminated through peer-reviewed journals,
international conferences, and meetings and events
organised with local stakeholders.
Trial registration number: NCT02773095.
INTRODUCTION
Over the last two decades, the prevalence of
non-communicable diseases (NCDs) globally
has increased signiﬁcantly for a variety of
reasons including population ageing and
increased exposure to risk factors such as
tobacco use, harmful consumption of alcohol,
physical inactivity, and unhealthy diets.1 2 The
NCD burden in low and middle income coun-
tries is growing particularly fast.3 In Kenya,
NCDs account for 27% of deaths (about
370 000 per year) among people between 30
and 70 years old, and the probability of dying
prematurely from NCDs is about 18%.4 5
As in most low and middle income coun-
tries, medicines to treat NCDs are difﬁcult to
access or too expensive for many Kenyan
households.6 7 According to a recent survey,
only 33% of Kenyan patients prescribed
NCD medicines have them in their home.
Furthermore, 82% of NCD medicines pur-
chased are paid for out-of-pocket.8 As a
Strengths and limitations of this study
▪ To the best of our knowledge, this will be the
first experimental evaluation of an industry-led
access to medicines initiative in a developing
country.
▪ This study will combine data from facility and
household interviews conducted at baseline,
midline, and end-line with quarterly surveillance
data from phone-based interviews to estimate
trends in access to medicines over time.
▪ The study will evaluate impacts on medicine
availability and price and not on patient health
outcomes.
▪ The results of this study will help inform the
design and evaluation of access to medicines
initiatives in the future.
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result, NCD sequelae which are often avoidable with
proper treatment account for more than half of hospital
admissions in the country.9
Global stakeholders have signalled a commitment to
confronting the growing burden of NCDs by including
them in the Sustainable Development Goals.10 Increasing
access to essential NCD medicines is a fundamental part
of these efforts.11 Against this backdrop, Novartis/Sandoz
has recently launched Novartis Access, an initiative to
provide a low-cost portfolio of NCD medicines in 30 low
and middle income countries over the next 5 years.12
The portfolio includes patented and generic medicines
to treat diabetes, hypertension, heart failure, hyperlipid-
aemia, breast cancer and asthma. All medicines in the
portfolio are included on the WHO’s Model List of
Essential Medicines.13 Novartis Access will be implemen-
ted in programme countries in close partnership with
local governments and non-governmental organisations,
with a focus on strengthening public sector systems.
In 2016, Kenya will be the ﬁrst country to receive
Novartis Access medicines. The portfolio of medicines will
be distributed solely through the Mission for Essential
Drugs and Supplies (MEDS), the main supplier for the
large network of private (often faith-based) non-proﬁt
health facilities in the country, and also a key supplier
for public facilities. In Kenya, NCD services are provided
in the public and private non-proﬁt sectors at dispensar-
ies up through hospitals, and these facilities will be eli-
gible to purchase Novartis Access medicines. Pricing
policies for NCD medicines sold through the public
sector in Kenya are determined at the county level, and
substantial variation exists. The price paid by patients in
the public sector is generally lower than in the private
sector. For example, the median public sector price paid
for glibenclamide, a common treatment for diabetes, is
less than one-quarter of the price paid in the private for-
proﬁt sector.14 Private for-proﬁt facilities and drug
sellers will not be allowed to purchase Novartis Access
medicines, and will continue to purchase standard
Novartis products through existing mechanisms.
This study will be a cluster-randomised controlled trial
evaluating the impact of Novartis Access on the availability
and price of NCD medicines at health facilities and house-
holds in Kenya. Eight counties will be randomly assigned
to the intervention or control group. In the intervention
counties, public and non-proﬁt health facilities will be
allowed to order low-cost Novartis Access NCD medicines.
The results of this evaluation will provide much needed
rigorous evidence of the impact of a new large NCD medi-
cine access programme, and will help inform the design
and evaluation of similar initiatives in the future. It will
also provide Novartis with valuable feedback that can be
used to improve Novartis Access as it expands.
METHODS AND ANALYSIS
Participants, interventions, and outcomes
Eight counties have been non-randomly selected for
inclusion in the study. Of the 47 total counties in Kenya,
17 counties were excluded because they do not purchase
medicines from MEDS, and an additional 15 counties
that had not purchased at least US$100 000 worth of
medicines through MEDS in the previous year were
excluded. Three counties were excluded due to security
concerns, and four additional counties were excluded to
eliminate shared borders in the ﬁnal sample, to minim-
ise the risk of contamination between intervention and
control counties. When considering counties with
shared borders, those with the lower volume of MEDS
purchases in the previous year were excluded.
Counties have on average: 5 public and private non-
proﬁt level ﬁve county referral hospitals; 3 public level
four subcounty hospitals; 15 public and private non-proﬁt
level three health centers; and 85 public and private non-
proﬁt level two dispensaries (table 1). All 184 eligible
level 3–5 facilities will be included in the study, and 200
level 2 dispensaries will be randomly selected for inclu-
sion. For each facility included in the study, one private
drug seller identiﬁed as the main alternative for that facil-
ity will be identiﬁed and included. Private drug sellers
include registered pharmacies and drug stores, but not
unregistered dispensing doctors or market sellers.
A total sample of 800 households will be randomly
selected from the eight study counties (400 from
Novartis Access counties; 400 from control counties)
using a two-stage sampling procedure. In the ﬁrst stage,
10 enumeration areas (EAs) will be selected in each
county with probability proportional to size based on
data from the most recent census. EAs have on average
around 100 households and may be comprised of one
or more villages. Then, in the second stage, 10 eligible
households will be randomly selected in each EA and
recruited into the study. All households in the EA will be
listed in a random order, and enumerators will proceed
down the list until 10 eligible households are identiﬁed.
Households will be eligible if at least one member
18 years or older has been previously diagnosed and pre-
scribed medicine for NCDs addressed by Novartis Access.
All members of the household who ﬁt that criterion will
be recruited for the study. Based on the prevalence of
the relevant NCD conditions in Kenya, we estimate that
20% of all households will meet the inclusion criterion.8
In the intervention counties, public and private non-
proﬁt health facilities will be allowed to purchase the
portfolio of 15 low-cost Novartis Access NCD medicines
Table 1 Public and private non-profit health facilities per
county
Average number of
facilities per county
Type of facility (level) Public Private non-profit
Dispensaries (2) 50 35
Health centres (3) 10 5
Subcounty hospitals (4) 3 0
County referral hospitals (5) 3 2
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through MEDS (table 2). The medicines will be sold dir-
ectly to MEDS at an average cost of US$1 per monthly
dose. Facility-level administrative data on NCD medicine
purchases obtained from MEDS will be used to monitor
the implementation of the intervention.
The primary outcomes of interest are medicine avail-
ability and price at health facilities, and medicine avail-
ability, price, and expenditures at patients’ households.
At facilities, availability will be measured for each disease
area and deﬁned as having at least one treatment medi-
cine in stock, whether a Novartis Access medicine, a
generic equivalent, or a therapeutic alternative (table 3).
At households, medicine availability will be measured
in the same manner for each diagnosed disease. At facil-
ities, price will similarly be measured for each disease
area and deﬁned as the lowest per unit price for a treat-
ment medicine. At households, price will be measured
for each diagnosed disease and deﬁned as the per unit
price paid for most recent treatment purchased.
Household expenditures will be measured for each diag-
nosed disease and deﬁned as total spending on treat-
ment medicines in the previous 4 weeks. The price of
medicines sold by registered private for-proﬁt drug
sellers is an important secondary outcome. Finally,
Table 2 Novartis Access portfolio, generic equivalents, and therapeutic alternatives
Disease area
Novartis Access
Medicines*
Generic
Equivalents Therapeutic alternatives
Hypertension and heart failure Furosemide†
Amlodipine†
Bisoprolol
Valsartan
Ramipril
Hydrochlorothiazide
Furosemide†
Amlodipine†
Bisoprolol
Valsartan
Ramipril
Hydrochlorothiazide
Atenolol
Captopril
Dyslipidaemia Simvastatin Simvastatin
Diabetes type 2 Vildagliptin
Glimepiride
Metformin
Glimepiride
Metformin
Glibenclamide
Breast cancer Letrozole
Anastrozole
Tamoxifen
Letrozole
Tamoxifen
Asthma Salbutamol Salbutamol
*The Novartis Access portfolio also includes amoxicillin for the treatment of child pneumonia. Medicines for other acute diseases will be
surveyed as acute disease comparators.
†Treatment for hypertension only.
Table 3 Primary outcomes
Primary
outcome Level Disease areas Definition
Availability Facility Hypertension
Heart failure
Dyslipidaemia
Diabetes type 2
Breast cancer
Asthma
At least one treatment medicine in stock, whether Novartis Access,
generic equivalent, or therapeutic alternative
Household Each diagnosed
disease
At least one treatment medicine in the home, whether Novartis Access,
generic equivalent, or therapeutic alternative
Price Facility Hypertension
Heart failure
Dyslipidaemia
Diabetes type 2
Breast cancer
Asthma
Lowest per unit price for a treatment medicine in stock
Household Each diagnosed
disease
Per unit price paid for most recent treatment purchased
Expenditure Household Each diagnosed
disease
Total spending on treatment medicines in the previous four weeks
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patient and health worker perceptions of NCD medicine
access will also be explored.
Data will be collected at facilities and households
using a structured questionnaire at baseline prior to the
implementation of Novartis Access, at midline after 1-year,
and at end-line after 2 years (ﬁgure 1). Survey instru-
ments will be adapted from tools previously developed
for measuring medicine access by the WHO and Health
Action International, which have been validated in
several countries.15 16
At each interview, a subsample of facilities and house-
holds will also be administered a qualitative interview.
Additional surveillance data will be collected quarterly
from facilities and a randomly selected subsample of
households using a structured questionnaire adminis-
tered over the phone.
The study is powered to detect a 10 percentage point
increase in household availability of medicines due to
Novartis Access at α=0.05, assuming an intracluster correl-
ation coefﬁcient of 0.05, 10% loss to follow-up, and 33%
availability in the control group.8 The study is also
powered to detect a 10 percentage point increase in
facility availability in the Novartis Access group at α=0.05,
assuming 50% availability in the control group.
Assignment of the intervention
The eight counties selected for inclusion in the trial will
be randomised to the intervention or control group
using a covariate constrained randomisation method to
maximise balance on nine demographic and health vari-
ables: total population; population density; proportion
of the population in urban areas; poverty rate; number
of health facilities; physicians per capita; health spend-
ing per capita; overall value ordered through MEDS in
previous year; and proportion of value ordered through
MEDS in previous year by private non-proﬁt versus
public health facilities.17 Allocation will be masked from
baseline data collectors. However, it will not be possible
to mask the intervention from participants.
Data collection, management, and analysis
The health facility questionnaire has been adapted from
an instrument developed by the WHO and Health
Action International and previously used in Kenya, and
captures information on medicine availability and medi-
cine price.14 Facility data will be collected for Novartis
Access NCD medicines, generic equivalents, and alterna-
tives. Data will also be collected for a set of acute disease
medicines to provide contextual information. The
household questionnaire includes information on demo-
graphics, household assets, and key information on med-
icines, including whether prescribed NCD medicines are
currently at the home, locations where medicines are
most often purchased, prices paid, and overall house-
hold expenditures on medicines (and on other goods).
The household questionnaire will be translated into
local languages as appropriate.
A subsample of health facilities and subsample of
households will also be administered a qualitative inter-
view during baseline, midline, and end-line visits. A pur-
poseful subsample of ﬁve level 2 dispensaries and ﬁve
level 3–5 facilities will be selected in each county (80
facilities in total), and one staff member will be selected
for the interview. A purposeful subsample of 10 house-
holds in each county (80 households in total) will be
selected for qualitative interviews, which will be adminis-
tered to one individual in the household who also com-
pletes the general household survey. Facilities and
households will be selected for qualitative interviews to
maximise variation in the viewpoints represented (eg,
age, disease, wealth). The qualitative instrument has
been designed to explore in depth key issues related to
medicine access.
Surveillance data will be collected quarterly from all
health facilities and a subsample of households. For
health facility surveillance, a shortened version of the
structured questionnaire with basic information on
medicine availability and price will be administered over
the phone each month to a rotating one-third sample of
health facilities, such that all facilities are surveilled once
per quarter. For household surveillance, a random
sample of half of all study households with phones will
be selected; half of study households will not be sur-
veilled at all, to allow for an analysis of the potential
effect of surveillance on household behaviour. Those
households selected for surveillance will be administered
a shortened version of the structured questionnaire with
basic information on medicine availability and purchases
over the phone. As with health facilities, a rotating
one-third sample of households selected for surveillance
will be surveyed by phone each month, such that all sur-
veilled households are surveyed once per quarter. A 5%
subsample of the surveilled health facilities and house-
holds will be visited in person to audit phone responses
and conﬁrm medicine price and availability through
direct observation.
A local partner who specialises in the implementation
of randomised controlled trials will manage ﬁeldwork.
Data will be collected electronically using Census and
Survey Processing System (CSPro) software on tablets
and managed using Microsoft Access software.
Data on baseline characteristics of health facilities and
households will be compared across groups to assess
balance. The impact of Novartis Access will be estimated
using intention-to-treat analysis. Analysis of covariance
(ANCOVA) methods will be used to control for potential
baseline differences between groups.18 All impact ana-
lyses will be conducted using Stata statistical software
(StataCorp. Stata Statistical Software: Release 14. College
Station, TX: StataCorp LP, 2015). Surveillance data will
be explored to understand trends in outcomes over
time. Finally, transcripts from qualitative interviews will
be analysed using NVivo software (NVivo qualitative data
analysis Software; QSR International Pty Ltd. Version 11,
2015). Responses will be coded based on overall
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Figure 1 (A) Flow of facilities. (B) Flow of household participants. NCD, non-communicable disease.
Rockers PC, et al. BMJ Open 2016;6:e013386. doi:10.1136/bmjopen-2016-013386 5
Open Access
 o
n
 5 July 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2016-013386 on 25 November 2016. Downloaded from 
perceptions of medicine availability, price, and quality,
on perceptions of barriers to medicine access, and on
perceptions of Novartis Access medicines compared with
other medicines.
Limitations
There are important limitations to this work. First,
household data on medicine prices will rely on partici-
pant reporting which may be subject to recall bias. In
particular, if patients purchased multiple medicines at
once, they may have difﬁculty recalling prices paid for
individual medicines. Second, households without a
mobile phone will be excluded from surveillance data
collection, which may introduce bias. However, high
mobile phone coverage is expected in the study popula-
tion—according to the 2014 Demographic and Health
Surveys, around 90% of households in Kenya have a
mobile phone.19 A thorough analysis of this potential
bias will be conducted using household baseline data.
Finally, no health outcome data will be collected, and it
will therefore not be possible to draw any conclusions as
to the health impacts of Novartis Access. If the interven-
tion is found to improve medicine price and availability,
future studies should explore impacts on health
outcomes.
DISSEMINATION
Informed consent will be obtained from all participants
at the start of the trial. If a household member expresses
interest in participating in the study, a study team
member will explain the study in detail, verify eligibility,
and obtain informed written consent where appropriate.
Consent is not required prior to eligibility screening. As
is standard in Kenya, all participants in the health facility
and household surveys will be given compensation for
their time. They will each receive 30 min of mobile
phone airtime, a value of US$0.53.
All identifying information collected from participants
will be kept strictly conﬁdential through the use of
unique identifying numbers. An initial tracking ﬁle
including participant names, study numbers, and
address information, will be generated to allow for
follow-up activities, but will be kept separate from all
other data and will be password-protected, maintained
on computers in locked ofﬁces, and only accessible to
authorised study personnel. It will be destroyed within
6 months after the study is completed. All study results
presented in written form will be aggregated, with no
individual identifying information.
The ﬁndings of the trial will be disseminated through
peer-reviewed journals, international conferences, and
meetings and events organised with local and inter-
national stakeholders. The trial has been registered at
Clinicaltrials.gov (NCT02773095). Finally, a website has
been developed to serve as a repository for study infor-
mation and documentation, and to establish a standard
of transparency: sites.bu.edu/novartisaccessevaluation.
All study materials including quantitative and qualitative
instruments are available on this website.
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